BillionToOne, Inc. completed an initial public offering, raising approximately $314 million by selling over 5 million shares.
Quiver AI Summary
BillionToOne, Inc., a molecular diagnostics company focused on creating accessible and accurate tests, recently completed its upsized initial public offering (IPO), selling 5,233,765 shares of Class A common stock at $60.00 per share, which raised approximately $314 million before expenses. The offering included full exercise of the underwriters’ option for an additional 682,665 shares. Shares of BillionToOne began trading on the Nasdaq Global Select Market under the ticker “BLLN” on November 6, 2025. J.P. Morgan, Piper Sandler, Jefferies, and William Blair served as joint book-running managers for the IPO, with Stifel, Wells Fargo Securities, and BTIG also involved. The relevant registration statement was effective as of November 5, 2025, and a prospectus detailing the offering is available through the SEC and various financial contacts provided in the release.
Potential Positives
- BillionToOne successfully closed its upsized initial public offering, raising approximately $314.0 million, indicating strong investor interest and financial backing for its growth initiatives.
- The company’s Class A common stock began trading on the Nasdaq Global Select Market, enhancing its visibility and credibility in the financial marketplace.
- The offering included the full exercise of the underwriters’ option to purchase additional shares, demonstrating confidence from underwriters and a robust demand for the company’s stock.
- BillionToOne has a unique patented technology, the Quantitative Counting Templates™ (QCT™), which positions the company as a leader in molecular diagnostics, potentially attracting further investment and partnerships.
Potential Negatives
- The press release does not provide any details about the financial health of the company beyond the IPO, which could raise concerns for potential investors regarding ongoing operations and sustainability.
- The reliance on underwriters for the IPO could indicate a lack of direct market confidence, as the company has opted for external backing rather than a self-managed approach.
- There is no mention of how the funds raised from the IPO will be utilized, leaving stakeholders uncertain about the company's strategic direction post-IPO.
FAQ
What is BillionToOne's recent public offering?
BillionToOne closed its upsized initial public offering of 5,233,765 shares of Class A common stock, raising approximately $314 million.
What is the ticker symbol for BillionToOne?
BillionToOne's Class A common stock trades on the Nasdaq Global Select Market under the ticker symbol "BLLN."
Who were the underwriters for the offering?
J.P. Morgan, Piper Sandler, Jefferies, and William Blair acted as joint book-running managers for the offering.
How can I obtain the prospectus for BillionToOne's offering?
The prospectus can be obtained from the underwriters listed in the press release or on the SEC's website.
What technology does BillionToOne utilize in its diagnostics?
BillionToOne uses patented Quantitative Counting Templates™ (QCT™) for accurate DNA molecule counting at the single-molecule level.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
MENLO PARK, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the closing of its upsized initial public offering of 5,233,765 shares of its Class A common stock, which includes the exercise in full of the underwriters’ option to purchase an additional 682,665 shares of Class A common stock at a public offering price of $60.00 per share, less underwriting discounts and commissions. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by BillionToOne, were approximately $314.0 million. BillionToOne’s Class A common stock began trading on the Nasdaq Global Select Market on November 6, 2025, under the ticker symbol “BLLN.”
J.P. Morgan, Piper Sandler, Jefferies and William Blair acted as joint book-running managers for the offering. Stifel, Wells Fargo Securities and BTIG also acted as book-running managers for the offering.
A registration statement on Form S-1 related to these securities has been filed with the U.S. Securities and Exchange Commission and became effective on November 5, 2025. A prospectus relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC's website at www.sec.gov . The offering was made only by means of a prospectus. Copies of the prospectus may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email: [email protected] and [email protected] ; Piper Sandler & Co., Attention: Prospectus Department, 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401, by telephone at (800) 747-3924, or by email at [email protected] ; Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) 821-7388 or by email at [email protected] ; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, Illinois 60606, by telephone at (800) 621-0687 or by email at [email protected] .
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About BillionToOne
Headquartered in Menlo Park, California, BillionToOne is a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all. The company's patented Quantitative Counting Templates™ (QCT™) molecular counting platform is the only multiplex technology that can accurately count DNA molecules at the single-molecule level.
Investor Contact
[email protected]
Media Contact
[email protected]
